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COPDAbstract Introduction: Vitamin D deﬁciency is prevalent among patients with chronic obstructive
pulmonary disease (COPD) and comes to be more frequent with increased disease severity. We
aimed to assess the role of vitamin D supplementation in patients with severe COPD.
Patients and methods: We studied 30 patients with severe COPD and vitamin D deﬁciency. All
patients received oral vitamin D3 50,000 IU once weekly for 8 weeks, followed by a daily dose of
800 IU thereafter. Pulmonary function tests, six minute walk test (6MWT), maximum inspiratory
pressure (MIP), maximum expiratory pressure (MEP), C-reactive protein (CRP), and serum vita-
min D level were assessed at the start of the study and 1 year later. The frequency of exacerbations
was recorded a year before and a year after vitamin D supplementation.
Results: The mean serum vitamin D level was 11.80 ± 2.40 ng/dl and reached 55.30 ± 5.65 ng/
dl a year after vitamin D intake (p< 0.001). We found a signiﬁcant improvement in dyspnea scale
(p< 0.003), 6MWT (p< 0.001), MVV (p< 0.001), MIP (p= 0.006), MEP (p< 0.001), coupled
with a decrease in disease exacerbations (p< 0.001) and CRP (p< 0.001) a year after vitamin D
replacement. However, the FEV1 and FVC did not differ signiﬁcantly.
Conclusion: Vitamin D replacement improved dyspnea, physical performance and decreased the
frequency of exacerbation in severe COPD patients with vitamin D deﬁciency.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Chronic obstructive pulmonary disease (COPD) is a common
preventable and treatable disease, characterized by persistent
air ﬂow limitation that is usually progressive and associated
with an enhanced chronic inﬂammatory response of airwaysrculosis.
Table 1 Modiﬁed Medical Research Council dyspnea scale.
Grade Symptom
0 I only get breathless with strenuous exercise
1 I get short of breath when hurrying on level ground or
walking up a slight hill
2 On level ground, I walk slower than people of the same age
because of breathlessness, or have to stop for breath when
walking at my own pace
3 I stop for breath after walking about 100 yards or after a
few minutes on level ground
4 I am too breathless to leave the house or I am breathless
when dressing
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comorbidities contribute to the overall severity in individual
patients [1].
Patients with COPD are at high risk of vitamin D deﬁciency
due to lower food intake, reduced synthesis with skin aging,
lack of outdoor activity and sun exposure, increased catabo-
lism by glucocorticoids, impaired activation because of renal
dysfunction, and a lower storage capacity in muscles or fat
due to wasting [2].
Vitamin D is a fat-soluble hormone precursor that plays an
important role in bone metabolism and seems to have anti-
inﬂammatory and immune-modulating properties. Vitamin D
is present in 2 forms. Ergocalciferol, or vitamin D2, is present
in plants and some ﬁsh. Cholecalciferol, or vitamin D3, is
synthesized from 7-dehydrocholesterol in the skin by sunlight.
The vitamin undergoes two consecutive hydroxylations, one
in the liver to 25(OH)D (the inactive form of vitamin D)
and the other in the kidneys to 1,25(OH)D, its active form,
by the enzyme 1a hydroxylase [3,4].
Studies have demonstrated a role of vitamin D in enhanced
eradication of intracellular pathogens like Mycobacterium
tuberculosis [5], killing of a number of antibiotic-resistant bac-
teria, viruses and Chlamydia [6,7] and vitamin D deﬁciency
may contribute to chronic respiratory infection and airway
colonization [8]. Different lines of evidence also support a role
of vitamin D in skeletal muscle health. Low levels of serum
vitamin D (25-OHD) have been associated with reduced skel-
etal muscle strength and increased risk of falls while vitamin D
supplementation improved balance and reduced falls by
approximately 20% [9,10].
Vitamin D deﬁciency is prevalent among patients with
COPD and comes to be more frequent with increased disease
severity [11]. In participants with severe vitamin D deﬁciency
at baseline, supplementation may reduce exacerbations [12].
According to a recent meta-analysis, the beneﬁts of supple-
mentation were only present when baseline 25-OHD levels
are very low (<10 ng/ml) [13]. Nevertheless, because large
cross-sectional data suggest that muscle strength continues to
increase from 25-OHD levels of 9 ng/ml to 37 ng/ml [14], it
can be speculated that the beneﬁcial effects on the muscle
are only seen when higher doses of supplementation are given
[15].
In this study, we aimed to evaluate the effect of vitamin D
supplementation on the symptoms, pulmonary function tests,
respiratory muscle strength and physical performance in
vitamin D deﬁcient patients with severe COPD.
Patients and methods
The study design was prospective cohort pre-post study.
Between March 2011 and February 2013, 30 COPD patients
(26 male and 4 female, mean age 66.7 years) diagnosed as
severe COPD were included. Severe disease was established
according to GOLD criteria [1] (FEV1/FVC was <0.70 and
post-bronchodilator FEV1 was <50% from predictive value).
All patients had serum 25-OHD deﬁciency (levels <20 ng/ml).
Patients accepted to participate by giving informed consent.
The proposal of this study was approved by the Institutional
Ethics Committee. All patients were subjected to a complete
history taking, thorough clinical examination. Demographic
data were systematically recorded. Dyspnea in daily lifeactivity was assessed according to the Modiﬁed Medical
Research Council (MMRC) dyspnea scale which spans from
grade 0 through 4 as shown in Table 1.
Six minute walk test (6MWT)
The test measures the distance a patient can quickly walk on a
ﬂat, hard surface in a period of 6 min. The test was performed
according to guidelines set by the American Thoracic Society
[16]. In brief, the patient rested on a chair, located near the
starting position, for 10 min before the test. No ‘‘warm-up’’
period before the test was given. The patient was instructed
to walk as far as possible for 6 min and walk back and forth
in a 30 m long, meter-by-meter marked hallway. The patient
was informed that 6 min is a long time to walk, which means
he would be exerting himself, probably get out of breath or
become exhausted but he would be permitted to slow down,
to stop, to rest as necessary or lean against the wall while rest-
ing, and resume walking as soon as he was able to. Pulse oxim-
etry was attached. The baseline heart rate was measured and
oxygen saturation (SpO2) was recorded before and after the
test. Upon completion of the test, dyspnea and fatigue level,
number of laps, and additional distance covered were
recorded. The total distance was then calculated.
Pulmonary function tests (PFT)
Pulmonary function tests were performed using Jaegar Type
Masterscreen-PFT machine, VIASYS Healthcare GmbH,
CareFusion Corporation, Hoechberg, Germany. Forced expi-
ratory volume in 1 s (FEV1), maximum voluntary ventilation
(MVV), forced vital capacity (FVC), forced expiratory ﬂow
(FEF25), forced expiratory ﬂow (FEF50), and forced expira-
tory ﬂow (FEF75) were recorded.
Maximal inspiratory pressure (MIP) and maximal expiratory
pressure (MEP)
Measurement of MIP and MEP required mechanical pressure
gauge connected to mouthpiece. The device contained a small
hole of 1 mm diameter and 20–30 mm in length which allowed
air leak to prevent the patient from generating pressure by
cheek muscles as described previously [17].
For MIP, a new rubber mouthpiece with ﬂanges was placed
on the device. The patient was instructed to seal his/her lips
ﬁrmly around the mouthpiece and to exhale slowly and
Table 2 Demographic characteristics of the study patients.
Variable
Age in years (mean ± SD) 66.7 ± 8.5
Gender
Male, no. (%) 26 (86.7)
Female, no. (%) 4 (13.3)
Residency
Rural, no. (%) 4 (13.3)
Urban, no. (%) 26 (86.7)
Smoking, pack-year (mean ± SD) 48.4 ± 8.1
Note: SD: standard deviation.
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inspiratory pressure for 1.5 s and sustained the largest negative
pressure for at least 1 s. Regarding MEP, a new rubber mouth-
piece with ﬂanges was also placed. The patient was instructed
to inhale completely to total lung capacity then push the
mouthpiece against his/her lips and teeth as hard as possible.
The patient maintained expiratory pressure for 1.5 s and sus-
tained the largest positive pressure for at least 1 s. In both
MIP and MEP, the patient was allowed to rest for 1 min
and then repeat the test 5 times. The goal was for the variabil-
ity among measurements to be less than 10 cmH2O [18].
Serum vitamin D
Serum samples were centrifuged, aliquoted and stored at
70 C until analysis. Quantitative determination of serum
25-OHD was performed using Chemiluminescent
Immunoassay technology (25-hydroxyvitamin D total assay,
Cobas e-analyzer, Roche Diagnostics, Mannheim, Ger-
many). The concentration of each sample was calculated auto-
matically either in ng/ml or nmol/L using the conversion
factors (nmol/L · 0.40 = ng/ml and ng/ml · 2.50 = nmol/L).
Frequency of COPD exacerbation
The frequency of exacerbations a year before and a year after
vitamin D supplementation was recorded. Exacerbation was
deﬁned as acute events in COPD patients beyond day to day
variation and needed change of treatments [1].
Vitamin D supplementation
All patients received oral vitamin D3 50,000 IU once weekly
for 8 weeks, followed by a daily dose of 800 IU thereafter.
Serum vitamin D level was measured a year after the start of
vitamin D supplementation. The previous parameters were
re-assessed a year after vitamin D replacement.
Statistical analysis
IBM SPSS statistics version 21 (IBM SPSS New York,
U.S.A) was used to analyze the data. Categorical variables
were expressed as numbers and percentages and continuous
variables as mean ± standard deviation. Fisher exact test
was used to detect signiﬁcant difference between categorical
variables. Differences in means were compared using t-test.
A p-value of <0.05 was considered statistically signiﬁcant.
Results
Of 30 severe COPD patients with vitamin D deﬁciency, 26
(86.7%) were from urban areas and 4 (13.3) from rural areas.
Mean smoking index was (48.4 ± 8.1) pack-year. The demo-
graphic characteristics of the study patients are shown in
Table 2.
A signiﬁcant improvement in MMRC dyspnea scale
(2.20 ± .81 vs. 1.77 ± .57, p= 0.003), 6MWT (93.57 ±
13.48 vs. 113.23 ± 10.03, p< 0.001), and frequency of exacer-
bation (1.80 ± 0.81 vs. 1.03 ± 0.57, p< 0.001) was noticed
1 year after vitamin D replacement. CRP was signiﬁcantlyreduced (23.67 ± 18.91 vs. 13.00 ± 14.59, p< 0.001)
(Table 3). In the meantime, the MIP (75.87 ± 8.81 vs.
82.13 ± 7.99, p= 0.006), MEP (78.43 ± 7.13 vs. 86.27 ±
6.63, p< 0.001), and MMV (43.13 ± 8.60 vs. 51.40 ± 8.35,
p< 0.001) showed a signiﬁcant improvement.
The mean percent predicted FEV1 in our COPD patients
was 38.27 ± 6.32, and FVC 60.53 ± 4.36 before vitamin D
supplementation. The FEV1, FVC and forced expiratory ﬂows
did not differ signiﬁcantly a year after vitamin D replacement
(Table 4).Discussion
We have found a signiﬁcant improvement of dyspnea, respira-
tory muscle strength and physical performance without paral-
lel improvement in pulmonary function tests like FEV1 and
FVC after supplementation of vitamin D over 1 year.
In the literature, a survey of 14,091 peopleP20 years of age
who had undergone spirometry, and in whom serum 25-OHD
levels had been measured, found a strong relationship between
serum concentrations of 25-OHD, FEV1, and FVC [19]. The
investigators attributed this in a number of ways in which vita-
min D might inﬂuence tissue remodeling and repair. These
included the inhibition of matrix metalloproteinases which
are involved in the digestion of extracellular matrix [20] and
the effects on the proliferation of ﬁbroblasts and synthesis of
collagen [21].
Monadi and colleagues [22] studied the relationship
between various COPD patients’ groups classiﬁed on the basis
of serum 25-OHD concentration and FEV. The researchers
found that mean FEV1 volumes increased with higher serum
25-OHD concentrations. However, the mean FEV1 differences
among groups did not reach to a statistically signiﬁcant level.
It is noteworthy that only 11% of their patients were vitamin
D deﬁcient and the proportion of those with severe COPD
(GOLD stages 3 and 4) were only 2.5%, and 1.3%
respectively.
In our study, we could argue why we could not ﬁnd a sig-
niﬁcant improvement in pulmonary function like FEV1,
FVC and ﬂows after supplementation of vitamin D. The study
was conducted on patients who were mostly elderly with estab-
lished severe COPD and probably had different confounders,
which could not allow them to beneﬁt from the effect of vita-
min D on tissue remodeling and repair.
Table 4 Pulmonary function tests, MIP and MEP before and after vitamin D replacement.
Before vitamin D After vitamin D p-Value
Mean ± SD Mean ± SD
FEV1 (% predicted) 38.27 ± 6.32 38.98 ± 6.50 0.670
FVC (% predicted) 60.53 ± 4.36 63.03 ± 4.79 0.074
FEF25 (% predicted) 44.50 ± 5.98 45.77 ± 6.33 0.111
FEF50 (% predicted) 39.40 ± 5.09 39.98 ± 5.34 0.659
FEF75 (% predicted) 30.63 ± 7.44 31.40 ± 7.12 0.446
MVV 43.13 ± 8.60 51.40 ± 8.35 0.001*
MIP 75.87 ± 8.81 82.13 ± 7.99 0.006*
MEP 78.43 ± 7.13 86.27 ± 6.63 <0.001*
Note: FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; FEF: forced expiratory ﬂow; MVV: maximum voluntary ventilation;
MIP: maximum inspiratory pressure; MEP: maximum expiratory pressure.
* Signiﬁcant p-value.
Table 3 Vitamin D level, dyspnea, 6MWT, CRP and frequency of COPD exacerbation before and after vitamin D replacement.
Before vitamin D After vitamin D p-Value
Mean ± SD Mean ± SD
Vitamin D (nmol/L) 11.80 ± 2.40 55.30 ± 5.65 <0.001*
Dyspnea scale 2.20 ± .81 1.77 ± .57 0.003*
6MWT (meters) 93.57 ± 13.48 113.23 ± 10.03 <0.001*
CRP (U/L) 23.67 ± 18.91 13.00 ± 14.59 <0.001*
Exacerbation/year (no.) 1.80 ± 0.81 1.03 ± 0.57 <0.001*
* Signiﬁcant p-value.
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test generally evaluates the global and integrated responses of
all the systems involved during exercise including the pulmon-
ary and cardiovascular systems, systemic circulation, periphe-
ral circulation, blood, neuromuscular units, and muscle
metabolism [16].
The effects of vitamin D on musculoskeletal, physiological
and neurophysiological function have been published in a
number of studies [23–26]. Bischoff-Ferrari and colleagues
[14] found that ambulatory persons (P60 years) with vitamin
D concentration 40–94 nmol/L had a better musculoskeletal
function in the lower extremities than at a concentration of
<40 nmol/L. Likewise, Menant et al. [23] found the associa-
tions between vitamin D insufﬁciency and impairments of
physiological and neuropsychological function that predispose
older people to fall. Bjerk et al. [24] reported an improvement
in physical performance, inspiratory muscle strength and max-
imal oxygen uptake with vitamin D supplementation.
Romme et al. [25] studied 151 COPD patients of whom 87
patients had vitamin D deﬁciency. Plasma 25hydroxy vitamin
D (25-OHD) concentration was positively associated with
bone density and exercise capacity as measured by 6MWT.
However, it was not associated with quadriceps muscle
strength. The researchers concluded that the majority of
COPD patients had vitamin D deﬁciency.
In contrast, Bjerk et al. [24] randomized 63 COPD patients
to daily cholecalciferol (2000 IU) or placebo for 6 weeks and
found that among patients with severe COPD, 2000 IU of
daily vitamin D for 6 weeks almost normalized the level of
25-(OH) D and when compared with placebo, the short-term
vitamin D supplementation had no noticeable effect on a sim-
ple measure of physical performance.Our analysis revealed a signiﬁcant decrease of CRP with
vitamin D replenishment. Several studies elucidated the anti-
inﬂammatory effects of vitamin D [27–29]. Moreno et al. [26]
reported that calcitriol [1,25(OH)2D3] regulates the expression
of several genes involved in prostaglandin (PG) metabolism
and signaling, thereby reducing the levels and biological activ-
ity of PGs. Nonn et al. [27] found that calcitriol up-regulates
the expression of mitogen-activated protein kinase phospha-
tase-5 (MKP-5) resulting in reduction of the level of expression
of pro-inﬂammatory cytokines. Studies that employed cDNA
microarrays to examine changes in gene expression in cancer
cells treated with calcitriol or its analogs identiﬁed many novel
calcitriol target genes, some of which could be important
molecular mediators of its potent anti-inﬂammatory effects
[28,29].
In our study, exacerbation decreased signiﬁcantly after vita-
min D replacement. This ﬁnding differs in a way from reports
of other investigators [12,30,31]. For example, Lehouck et al.
[12] found that the median time to ﬁrst exacerbation did not
differ signiﬁcantly between the studied groups, nor did exacer-
bation rates, FEV1, hospitalization, quality of life, and death.
However, a post hoc analysis in 30 participants with severe
vitamin D deﬁciency (serum 25-(OH) D level <10 ng/ml at
baseline) showed a signiﬁcant reduction of exacerbations in
the vitamin D group.
Similarly, other studies have found neither baseline serum
25(OH) D levels were predictive of subsequent acute exacerba-
tion in severe COPD [29] nor low levels were associated with
frequent exacerbation or increased susceptibility to worsening
by human rhinovirus [31].
In conclusion, vitamin D replacement in vitamin D deﬁ-
cient COPD patient may improve dyspnea, exercise capacity,
Vitamin D replacement in COPD patients with vitamin D deﬁciency 357and reduce the frequency of exacerbations. Further studies on
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